OcellO is an innovative biotech company offering services for drug discovery and early drug development. OcellO excels in clinically relevant in vitro 3D tumoroid assays, using Patient-derived xenograft (PDX) models and primary tumor cells (‘in vitro clinical trials’). We are experienced in working with different drug types incl. antibodies, antibody-drug conjugates (ADCs), small molecules and nucleic acids. Our technology and expertise has been successfully used for discovery and profiling of new molecules, for which now clinical trials are planned. Compound effects are thoroughly and sensitively quantified using OcellO’s unique high throughput, high content 3D imaging platform.